XERS - Xeris Positive Data And Other News: The Good Bad And Ugly Of Biopharma
Xeris Pharma Reports Positive Topline Data for Insulin Trial
Xeris Pharmaceuticals (XERS) reported positive data for its Phase 2 clinical trial for diabetes. The drug candidate XP-3924 is an o-formulation of pramlintide and insulin and the trial aimed to assess its potential in treating adults suffering from type 1 diabetes. The drug candidate aims to decrease post prandial glucose excursions and variability. It also aims to improve glycemic control.
The data showed that the drug candidate was able to bring 62.3 percent decline in hyperglycemia after the glucose challenge in comparison to Humulin